Biomarkers in Childhood-Onset Systemic Lupus Erythematosus

Cody, Ellen; Brunner, Hermine I.

doi:10.1016/j.rdc.2021.09.003

Cited by 4 publications

(3 citation statements)

References 57 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…There is a need for reliable, widely applicable and minimally invasive biomarkers to assist in diagnosing the disease and optimizing management. Currently, researches on childhood-onset SLE biomarkers have been active, with multiple gene-based and blood-based biomarkers being investigated, including the interferon signature, methylation status, neutrophil extracellular traps, S100 proteins, and complement split products 7 . These promising biomarkers hold potential for improving the diagnosis and treatment of childhood-onset SLE.…”

Section: Discussionmentioning

confidence: 99%

Serum RGC-32 in children with systemic lupus erythematosus

Huang

Feng

Niu

et al. 2023

Sci Rep

View full text Add to dashboard Cite

Childhood-onset systemic lupus erythematosus (SLE) can be more severe than adult patients. Early diagnosis and accurate evaluation of the disease are very important for the patients. Response gene to complement-32 (RGC-32) protein is the downstream regulator of C5b-9 complex which is the terminal pathway of complement activation. Complement system plays a very important role in the pathogenesis of SLE. RGC-32 in patients with SLE has not been reported yet. We aimed to examine the clinical value of RGC-32 in children with SLE. A total of 40 children with SLE and another 40 healthy children were enrolled for this study. Clinical data were obtained prospectively. Serum RGC-32 was determined by ELISA. We found that serum RGC-32 was significantly elevated in children with SLE than that in the healthy group. Serum RGC-32 was significantly higher in the children with moderately/severely active SLE than that in the children with no/mildly active SLE. Furthermore, serum RGC-32 level correlated positively with C-reactive protein, erythrocyte sedimentation rate and ferritin and correlated negatively with white blood cell counts and C3. RGC-32 may be involved in the pathogenesis of SLE. RGC-32 might become a good biomarker in the diagnosis and evaluation of SLE.

show abstract

Section: Discussionmentioning

confidence: 99%

Serum RGC-32 in children with systemic lupus erythematosus

Huang

Feng

Niu

et al. 2023

Sci Rep

View full text Add to dashboard Cite

show abstract

“…The aggressiveness of the disease is inversely proportional to the age at diagnosis, under 5 years of age atypical manifestations of the disease can also be observed (e.g., lack of autoantibodies). Therefore, an overall mortality rate of about three times the usual rate is estimated ( 3 – 5 ). Due to these considerations, the medical world is focusing its efforts on the discovery of new biomarkers (blood/urine) useful in the diagnosis, monitoring of jSLE, and predicting the response to treatment ( 6 , 7 ).…”

Section: Current Directions In Knowledgementioning

confidence: 99%

Undercover lung damage in pediatrics - a hot spot in morbidity caused by collagenoses

Lupu,

Sasaran,

Jechel

et al. 2024

Front. Immunol.

View full text Add to dashboard Cite

Connective tissue represents the support matrix and the connection between tissues and organs. In its composition, collagen, the major structural protein, is the main component of the skin, bones, tendons and ligaments. Especially at the pediatric age, its damage in the context of pathologies such as systemic lupus erythematosus, scleroderma or dermatomyositis can have a significant negative impact on the development and optimal functioning of the body. The consequences can extend to various structures (e.g., joints, skin, eyes, lungs, heart, kidneys). Of these, we retain and reveal later in our manuscript, mainly the respiratory involvement. Manifested in various forms that can damage the chest wall, pleura, interstitium or vascularization, lung damage in pediatric systemic inflammatory diseases is underdeveloped in the literature compared to that described in adults. Under the threat of severe evolution, sometimes rapidly progressive and leading to death, it is necessary to increase the popularization of information aimed at physiopathological triggering and maintenance mechanisms, diagnostic means, and therapeutic directions among medical specialists. In addition, we emphasize the need for interdisciplinary collaboration, especially between pediatricians, rheumatologists, infectious disease specialists, pulmonologists, and immunologists. Through our narrative review we aimed to bring up to date, in a concise and easy to assimilate, general principles regarding the pulmonary impact of collagenoses using the most recent articles published in international libraries, duplicated by previous articles, of reference for the targeted pathologies.

show abstract

“…Current routine laboratory tests are inadequate for identifying and monitoring jSLE, therefore, assessment of novel biomarker candidates has become an active area of investigation [99]. The most promising candidates present in urine and blood, with panels of proteins increasing sensitivity and specificity for diagnosis, monitoring and predicting treatment response [100,101 ▪ ,102–104].…”

Section: Monitoring Of Juvenile-onset Systemic Lupus Erythematosusmentioning

confidence: 99%

Current views on lupus in children

Smith

Lythgoe²,

Hedrich

2022

Current Opinion in Rheumatology

View full text Add to dashboard Cite

Purpose of reviewThis manuscript provides an update on clinical and pathophysiological features of juvenile-onset systemic lupus erythematosis (jSLE), challenges applying adult-derived classification criteria, and recent advances in treatment and care.Recent findingsSignificant scientific advances have improved the understanding of genetic factors (both genetic causes and risk alleles) and associated phenotypic features. Panels of urine/blood biomarker candidates aid in diagnosing jSLE, monitoring disease activity and predicting treatment response. Available classification criteria have been extensively assessed, with differences in clinical and immunological phenotypes of patients across age groups and ethnicities affecting their performance in jSLE. Therapeutic options remain limited and are based on protocols for adult-onset SLE patients. International efforts to inform development of a treat-to-target (T2T) approach for jSLE have yielded cohort-level evidence that target attainment reduces the risk of severe flare and new damage, and treatment compliance.SummaryRecent studies have significantly improved our understanding of jSLE pathogenesis, highlighting important differences between jSLE and adult SLE, and providing the basis of biomarker development and target-directed individualized treatment and care. Future work focused on development of a T2T approach in jSLE is eagerly awaited.

show abstract

Biomarkers in Childhood-Onset Systemic Lupus Erythematosus

Cited by 4 publications

References 57 publications

Serum RGC-32 in children with systemic lupus erythematosus

Serum RGC-32 in children with systemic lupus erythematosus

Undercover lung damage in pediatrics - a hot spot in morbidity caused by collagenoses

Current views on lupus in children

Contact Info

Product

Resources

About